Exact Mass: 484.2838116
Exact Mass Matches: 484.2838116
Found 99 metabolites which its exact mass value is equals to given mass value 484.2838116,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Gallopamil
C28H40N2O5 (484.29370700000004)
C - Cardiovascular system > C08 - Calcium channel blockers > C08D - Selective calcium channel blockers with direct cardiac effects > C08DA - Phenylalkylamine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker Same as: D08009
LysoPG(16:0/0:0)
LysoPG(16:0/0:0) is a lysophosphatidylglycerol. It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylglycerols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPG(16:0/0:0), in particular, consists of one chain of palmitic acid at the C-1 position.
[3-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] hexadecanoate
(13S)-ent-18-(E)-caffeoyloxy-8(17)-labden-15-oic acid|ent-18-(E)-Caffeoyloxy-8(17)-labden-15-oic acid
3-oxo-2,19alpha,22alpha-trihydroxy-24-nor-ursa-1,4,12-trien-28-oic acid
{(E)-3-(chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl linoleate
methyl-6alpha,18-dihydroxy-17-phenylacetoxy-kolavenoate
(5E,9Z)-6-bromo-5,9-hexacosadienoic acid methyl ester
11,12-epoxy-3,6-dihydroxy-24-norurs-3-en-2-on-(28->13)-olide
(3R,5S,10S,13R,16R,17S,20S,22R,23S,24S)-16,22-epoxy-21,23-lactone-3,24-dihydroxystigmasta-8,14-dien-28-one|vernoanthelcin B
12alpha-acetoxy-20,24-dimethyl-16,24-dioxoscalara-14,17-dien-24-ol-25,24-olide
12alpha-acetoxy-20,24-dimethyl-16,24-dioxoscalar-14,17-dien-25-oic acid|Ac-12alpha-12-Hydroxy-20,24-dimethyl-16,24-dioxo-14,17-scalaradien-25-oic acid
(5S,10S,13R,16R,17S,20S,21S,22R,23S,24S)-16,22;21,23-diepoxy-21,24-dihydroxystigmasta-8,14-dien-3,28-dione|16beta,22R;21,23S-diepoxy-21S,24-dihydroxy-5alpha-stigmasta-8,14-diene-3,28-dione|16??,22R;21,23S-Diepoxy-21S,24-dihydroxy-5??-stigmasta-8,14-diene-3,28-dione|vernoanthelcin F
N-(6-hydrazinyl-6-oxohexyl)-6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanamide
C22H40N6O4S (484.28316000000007)
Gly Pro Arg Arg
Gly Arg Pro Arg
Gly Arg Arg Pro
Asn Pro Arg Val
Asn Pro Val Arg
Asn Arg Pro Val
Asn Arg Val Pro
Asn Val Pro Arg
Asn Val Arg Pro
Pro Gly Arg Arg
Pro Asn Arg Val
Pro Asn Val Arg
Pro Arg Gly Arg
Pro Arg Asn Val
Pro Arg Arg Gly
Pro Arg Val Asn
Pro Val Asn Arg
Pro Val Arg Asn
Arg Gly Pro Arg
Arg Gly Arg Pro
Arg Asn Pro Val
Arg Asn Val Pro
Arg Pro Gly Arg
Arg Pro Asn Val
Arg Pro Arg Gly
Arg Pro Val Asn
Arg Arg Gly Pro
Arg Arg Pro Gly
Arg Val Asn Pro
Arg Val Pro Asn
Val Asn Pro Arg
Val Asn Arg Pro
Val Pro Asn Arg
Val Pro Arg Asn
Val Arg Asn Pro
Val Arg Pro Asn
PG(16:0/0:0)[U]
Biotin-XX hydrazide
C22H40N6O4S (484.28316000000007)
1-(DiphenylMethyl)-4-[(1RS,3E)-4-phenyl-1-[(E)-2-phenylethenyl)-3-buten-1-yl]piperazine
2-[cyclohexyl-[2-[5-(3,4-dimethoxyphenyl)-2-tetrazolyl]-1-oxoethyl]amino]-N-cyclopentylpropanamide
Gallopamil
C28H40N2O5 (484.29370700000004)
C - Cardiovascular system > C08 - Calcium channel blockers > C08D - Selective calcium channel blockers with direct cardiac effects > C08DA - Phenylalkylamine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker Same as: D08009
3-O-(2-O-Palmitoyl-L-glycero-3-phospho)-D-glycerol
(2R)-3-{[(2,3-dihydroxypropoxy)(hydroxy)phosphoryl]oxy}-2-hydroxypropyl hexadecanoate
4-[4-[(8R,9S,10R)-10-(hydroxymethyl)-6-(3-pyridinylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8R,9S,10S)-10-(hydroxymethyl)-6-(3-pyridinylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
4-[4-[(8S,9S,10S)-10-(hydroxymethyl)-6-(3-pyridinylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
4-[4-[(8S,9S,10S)-10-(hydroxymethyl)-6-(pyridin-4-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8S,9R,10S)-10-(hydroxymethyl)-6-(3-pyridinylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8R,9S,10R)-10-(hydroxymethyl)-6-(3-pyridinylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
[(2S)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] hexadecanoate
1-hexadecanoyl-sn-glycero-3-phospho-(1-sn-glycerol)
TG(26:7)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved